These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25468267)

  • 21. The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity.
    Levin M; Stark M; Assaraf YG
    Oncotarget; 2018 Mar; 9(24):16861-16882. PubMed ID: 29682190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KDM4B: A promising oncology therapeutic target.
    Ni F; Tang H; Cheng S; Yu Y; Yuan Z; Chen Y; Zhang E; Wang X
    Cancer Sci; 2024 Jan; 115(1):8-16. PubMed ID: 37923555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances with KDM4 Inhibitors and Potential Applications.
    Wu Q; Young B; Wang Y; Davidoff AM; Rankovic Z; Yang J
    J Med Chem; 2022 Jul; 65(14):9564-9579. PubMed ID: 35838529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JARID1 Histone Demethylases: Emerging Targets in Cancer.
    Harmeyer KM; Facompre ND; Herlyn M; Basu D
    Trends Cancer; 2017 Oct; 3(10):713-725. PubMed ID: 28958389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzo[
    Kim YJ; Lee DH; Choi YS; Jeong JH; Kwon SH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation.
    Young LC; McDonald DW; Hendzel MJ
    J Biol Chem; 2013 Jul; 288(29):21376-21388. PubMed ID: 23744078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substrate- and cofactor-independent inhibition of histone demethylase KDM4C.
    Leurs U; Lohse B; Rand KD; Ming S; Riise ES; Cole PA; Kristensen JL; Clausen RP
    ACS Chem Biol; 2014 Sep; 9(9):2131-8. PubMed ID: 25014588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family.
    Hillringhaus L; Yue WW; Rose NR; Ng SS; Gileadi C; Loenarz C; Bello SH; Bray JE; Schofield CJ; Oppermann U
    J Biol Chem; 2011 Dec; 286(48):41616-41625. PubMed ID: 21914792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and characterization of PKF118-310 as a KDM4A inhibitor.
    Franci G; Sarno F; Nebbioso A; Altucci L
    Epigenetics; 2017 Mar; 12(3):198-205. PubMed ID: 27767379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The KDM5 family of histone demethylases as targets in oncology drug discovery.
    Rasmussen PB; Staller P
    Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
    J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Jumonji histone demethylases as emerging therapeutic targets.
    Park SY; Park JW; Chun YS
    Pharmacol Res; 2016 Mar; 105():146-51. PubMed ID: 26816087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
    Duan L; Rai G; Roggero C; Zhang QJ; Wei Q; Ma SH; Zhou Y; Santoyo J; Martinez ED; Xiao G; Raj GV; Jadhav A; Simeonov A; Maloney DJ; Rizo J; Hsieh JT; Liu ZP
    Chem Biol; 2015 Sep; 22(9):1185-96. PubMed ID: 26364928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation.
    Liu K; Liu Y; Lau JL; Min J
    Pharmacol Ther; 2015 Jul; 151():121-40. PubMed ID: 25857453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
    Chu CH; Wang LY; Hsu KC; Chen CC; Cheng HH; Wang SM; Wu CM; Chen TJ; Li LT; Liu R; Hung CL; Yang JM; Kung HJ; Wang WC
    J Med Chem; 2014 Jul; 57(14):5975-85. PubMed ID: 24971742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases.
    Hoyle RG; Wang H; Cen Y; Zhang Y; Li J
    Mol Cancer Ther; 2021 Jan; 20(1):191-202. PubMed ID: 33203729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview.
    McCann TS; Sobral LM; Self C; Hsieh J; Sechler M; Jedlicka P
    Expert Opin Ther Targets; 2019 Apr; 23(4):267-280. PubMed ID: 30759030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat shock protein 90 (Hsp90) selectively regulates the stability of KDM4B/JMJD2B histone demethylase.
    Ipenberg I; Guttmann-Raviv N; Khoury HP; Kupershmit I; Ayoub N
    J Biol Chem; 2013 May; 288(21):14681-7. PubMed ID: 23589305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Jumonji histone demethylases are therapeutic targets in small cell lung cancer.
    Nguyen A; Nuñez CG; Tran TA; Girard L; Peyton M; Catalan R; Guerena C; Avila K; Drapkin BJ; Chandra R; Minna JD; Martinez ED
    Oncogene; 2024 Sep; 43(38):2885-2899. PubMed ID: 39154123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
    Rüger N; Roatsch M; Emmrich T; Franz H; Schüle R; Jung M; Link A
    ChemMedChem; 2015 Nov; 10(11):1875-83. PubMed ID: 26337137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.